Guardant Health, Inc. (NASDAQ:GH) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Guardant Health, Inc. (NASDAQ:GH) have been assigned a consensus rating of “Moderate Buy” from the fourteen brokerages that are presently covering the company, Marketbeat reports. One research analyst has rated the stock with a hold recommendation and thirteen have issued a buy recommendation on the company. The average 1 year target price among brokerages that have covered the stock in the last year is $36.83.

GH has been the subject of several research reports. Canaccord Genuity Group upped their target price on shares of Guardant Health from $30.00 to $38.00 and gave the stock a “buy” rating in a research report on Tuesday, June 4th. Guggenheim upgraded shares of Guardant Health from a “neutral” rating to a “buy” rating and set a $36.00 target price for the company in a research report on Friday. The Goldman Sachs Group cut their target price on shares of Guardant Health from $32.00 to $28.00 and set a “buy” rating for the company in a research report on Monday, April 15th. Stephens reiterated an “overweight” rating and issued a $44.00 target price on shares of Guardant Health in a research report on Friday, May 24th. Finally, Jefferies Financial Group assumed coverage on shares of Guardant Health in a research report on Monday, June 3rd. They issued a “buy” rating and a $32.00 target price for the company.

Guardant Health Stock Down 0.6 %

GH opened at $28.88 on Monday. The company has a fifty day moving average price of $24.98 and a 200-day moving average price of $22.94. The firm has a market capitalization of $3.53 billion, a P/E ratio of -7.37 and a beta of 1.15. The company has a debt-to-equity ratio of 16.70, a current ratio of 5.95 and a quick ratio of 5.66. Guardant Health has a one year low of $15.81 and a one year high of $41.06.

Guardant Health (NASDAQ:GH) last released its quarterly earnings results on Thursday, May 9th. The company reported ($0.94) EPS for the quarter, meeting analysts’ consensus estimates of ($0.94). The firm had revenue of $168.49 million during the quarter, compared to analyst estimates of $150.51 million. Guardant Health had a negative net margin of 76.34% and a negative return on equity of 246.47%. Equities research analysts expect that Guardant Health will post -3.31 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Guardant Health

Several hedge funds and other institutional investors have recently modified their holdings of GH. Van ECK Associates Corp raised its stake in Guardant Health by 29.4% in the fourth quarter. Van ECK Associates Corp now owns 2,702 shares of the company’s stock worth $73,000 after buying an additional 614 shares in the last quarter. Principal Financial Group Inc. raised its stake in Guardant Health by 10.5% in the fourth quarter. Principal Financial Group Inc. now owns 13,045 shares of the company’s stock worth $353,000 after buying an additional 1,240 shares in the last quarter. Wealthcare Advisory Partners LLC raised its stake in Guardant Health by 17.9% in the fourth quarter. Wealthcare Advisory Partners LLC now owns 8,596 shares of the company’s stock worth $233,000 after buying an additional 1,308 shares in the last quarter. Gotham Asset Management LLC raised its stake in Guardant Health by 4.8% in the third quarter. Gotham Asset Management LLC now owns 29,158 shares of the company’s stock worth $864,000 after buying an additional 1,335 shares in the last quarter. Finally, Oak Ridge Investments LLC raised its stake in Guardant Health by 8.5% in the first quarter. Oak Ridge Investments LLC now owns 18,540 shares of the company’s stock worth $382,000 after buying an additional 1,451 shares in the last quarter. 92.60% of the stock is owned by institutional investors.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.